FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia

...a, Inc. (KPA) is a specialty pharmaceutical company focused primarily in the area of cardiometabolic therapeutic area. The company, started in 2001 as proethic Pharmaceuticals, Inc., was acquired by KCL in September of 2008. A privately held company, KPA focuses its efforts on the acquisition, development, li...

Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (FDA approvable letter in May...

Cipher's revised NDA for CIP-TRAMADOL ER accepted for review by FDA

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (FDA approvable letter in May...

Cipher provides regulatory update for CIP-TRAMADOL ER

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (FDA approvable letter in May...

Cipher provides CIP-TRAMADOL ER regulatory update

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(TM). In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotr...

Cipher appoints Stefan Aigner to board of directors

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(TM). In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotr...

Cipher Appeals FDA's Decision On CIP-TRAMADOL ER

...roval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by proethic Pharmaceuticals under the label Lipofen(TM). In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotr...

Cipher reports third quarter fiscal 2007 results

...d into a licensing and distribution agreement with proethic Pharmaceuticals under which proethic was granted the exclusive right to market, se... and delivery of finished packaged product to proethic on schedule - Lipofen launched in U.S. market t...

ProEthic in Medical Technology

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

... Kowa Pharmaceuticals America, Inc. is a specialty pharmaceutical company focused primarily in the area of cardiology. The company, started in 2001 as proethic Pharmaceuticals, Inc., was acquired by Kowa Company, Ltd. in September of 2008. A privately held company, KPA focuses its efforts on the acquisition, ...

ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at American Headache Society Meeting

... be approved." Carl Whatley, Chairman and CEO of proethic Pharmaceuticals, stated, "The findings presented t...together. PRO-513 Development History In 2005, proethic obtained exclusive U.S. and Canadian marketing rig...wo dozen additional approvals during 2007. About proethic Pharmaceuticals, Inc. ...

ProEthic in Biological Technology

Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.

New Company to be Called Kowa Pharmaceuticals America NAGOYA, Japan and MONTGOMERY, Ala., Aug. 4 /PRNewswire/ -- Kowa Company, Ltd., a privately-held company headquartered in Nagoya, Japan, today announced the acquisition of ProEthic Pharmaceuticals, Inc., a privately-held specialty p...